Letter | Published:

Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain

Nature volume 257, pages 495496 (09 October 1975) | Download Citation

Subjects

Abstract

STUDIES on the pharmacology of the noradrenergic cyclic AMP-generating system in slices from the limbic forebrain of the rat1 and on adaptive properties of this system in conditions of persistent changes in the availability of nor-adrenaline (NA) have revealed that the system may serve as a model for the central NA receptor in this area, and that its sensitivity to NA increases or decreases when the availability of NA at the receptor site decreases or increases respectively2,3. Thus, hypersensitivity of the system has been achieved by treatment with reserpine2, a drug known to precipitate occasionally severe depressive reactions in man4, and the syndrome of which, when elicited in animals, is widely used as a model for depression5–7. Conversely, the monoamine oxidase (MAO) inhibitors, pargyline and nialamide, caused a marked reduction in the reactivity of the cyclic AMP-generating system to NA after chronic administration3. To determine whether or not antidepressant drugs which do not elevate the level of monoamines in brain share the effect of MAO inhibitors on the noradrenergic cyclic AMP-generating system, we studied the effect of the tricyclic antidepressants, desipramine and iprindole, on the reactivity of the system to NA. Desipramine blocks the uptake of NA through the neuronal membrane8,9 whereas iprindole neither blocks the neuronal uptake of NA nor alters its metabolism or turnover10,11, but is nevertheless a potent antidepressant12–14. In addition, we have tested the effect of electroconvulsive treatment (ECT), as it is generally accepted to be one of the most effective treatments for severe depression15.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , and , J. Pharm. Pharmac., 27, 125–128 (1975).

  2. 2.

    , , , and , J. Pharmac. exp. Ther. (in the press).

  3. 3.

    , , , and , Fedn Proc. 34, 269 (1975).

  4. 4.

    , and , Archs gen. Psychiat., 13, 483–494 (1975).

  5. 5.

    , , and , Ann. N.Y. Acad. Sci., 96, 279–288 (1962).

  6. 6.

    , , and , in Psychosomatic Medicine (edit. by Nodine, T. H., and Moyer, J. H.), 683–690 (Lea and Febiger, Philadelphia, 1962).

  7. 7.

    , and , in Antidepressant Drugs of Non-MAO Inhibitor Type (edit. by Efron, D. H., and Kety, S. S.), 1–19 (US Department of Health, Education and Welfare, Washington, DC, 1966).

  8. 8.

    , and , Acta Pharmac. Toxic., 22, 293–300 (1965).

  9. 9.

    , , , and , J. Pharmac. exp. Ther., 168, 272–282 (1969).

  10. 10.

    , and , J. Pharmac. exp. Ther., 183, 307–315 (1972).

  11. 11.

    , and , Psychopharmacologia, 40, 53–64 (1974).

  12. 12.

    , Dis. Nerv. Syst., 30, 818–824 (1969).

  13. 13.

    , Ill. Med. J., 128, 622–626 (1965).

  14. 14.

    , , and , J. ther. clin. Res., 1, 13–19 (1967).

  15. 15.

    , in Psychopharmacological Treatment (edit. by Denber, H. C. B.) 121–134 (Dekker, New York, 1975).

  16. 16.

    , and , Molec. Pharmac., 4, 367–378 (1968).

  17. 17.

    , , , and , Psychopharmacologia, 23, 201–211 (1972).

  18. 18.

    , , , and , J. biol. Chem. 193, 265–275 (1951).

  19. 19.

    , Proc. natn. Acad. Sci. U.S.A., 67, 305–312 (1970).

  20. 20.

    , and , Psychopharmacologia, 15, 305–309 (1969).

  21. 21.

    , , and , Psychopharmacologia, 35, 149–158 (1974).

Download references

Author information

Affiliations

  1. Vanderbilt University School of Medicine and Tennessee Neuropsychiatric Institute, Nashville, Tennessee 37232

    • JERZY VETULANI
    •  & FRIDOLIN SULSER

Authors

  1. Search for JERZY VETULANI in:

  2. Search for FRIDOLIN SULSER in:

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/257495a0

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.